Dr. Kris Discusses Driver Mutations Test False Negatives

Video

Dr. Mark G. Kris thoracic chair at Memorial Sloan-Kettering Cancer Center Discusses Driver Mutations Test False Negatives

Lead author Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the false negative rate discovered in the multicenter study focusing on the identification of driver mutations in tumor specimens in patients with lung adenocarcinoma. The study tested patients for KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, MEK1, and NRAS mutations using standard multiplexed assays and FISH for EML4-ALK rearrangements and MET amplifications.

Kris explains that a bad tissue sample is commonly the cause of false negatives and that measures are being, or are already, in place to assure the biopsy is not from the support structure and from the actual tumor cells. He reassures that false positives are extremely rare and if a test returns positive you can be certain it is accurate.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,